Adenocarcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Adenocarcinoma
- Therapeutic area
- Oncology
- adenocarcinoma
- adenocarcinoma
- adenocarcinoma NOS (morphologic abnormality)
- adenocarcinoma, malignant
- adenocarcinoma, no subtype (morphologic abnormality)
- adenocarcinomas
- ADNOS
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0004970
- Parent condition
- MONDO:0004993
Related records
Broader conditions (10)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by etiologic mechanism
- Epithelial neoplasm
- Glandular cell neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (395)
- Acinar cell carcinoma
- Acinar lung adenocarcinoma
- Acinar prostate adenocarcinoma, foamy gland variant
- Acinar prostate adenocarcinoma, signet ring variant
- Acinar prostate mucinous adenocarcinoma
- Acinic cell breast carcinoma
- Acquired cystic disease-associated renal cell carcinoma
- ACTH-producing pituitary gland carcinoma
- Adenoacanthoma
- Adenocarcinoma in situ
- Adenocarcinoma of gallbladder and extrahepatic biliary tract
- Adenocarcinoma of skene gland origin
- Adenoid cystic breast carcinoma
- Adenoid cystic carcinoma
- Adenoid cystic carcinoma of oropharynx
- Adenoid cystic carcinoma of the corpus uteri
- Adrenal cortex carcinoma
- Adrenocortical carcinoma, hereditary
- Adult hepatocellular carcinoma
- Aflatoxin-related hepatocellular carcinoma
Trials (614)
- -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
- 68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
- 68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
- 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
- 68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy
- A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
- A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
- A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
- A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
- A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone
- A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.
- A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
- A Long Term Safety Study With Atrasentan
- A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
- A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China
- A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Approved drugs (8)
- Docetaxel
- Docetaxel anhydrous
- Fluorouracil
- Irinotecan hydrochloride
- Mitomycin
- Pemetrexed tromethamine
- Thiotepa
- Tislelizumab
Drugs in development (62)
- Avelumab Phase 2
- AXP-107-11 Phase 1
- Belinostat Phase 1
- Bemarituzumab Phase 2
- Bevacizumab Phase 3
- Capecitabine Phase 3
- Capivasertib Phase 2
- Carboplatin Phase 2
- Ceralasertib Phase 2
- Cetuximab Phase 2
- Cisplatin Phase 3
- Crizotinib Phase 2
- Cyclophosphamide Phase 3
- Degarelix Phase 2
- Depatuxizumab Phase 2
- Domvanalimab Phase 3
- Durvalumab Phase 2
- Enzalutamide Phase 2
- Epirubicin hydrochloride Phase 3
- Everolimus Phase 1